Central Nervous System
CNS drugs have relatively seen lower success rates owing to a multitude of factors. Poor predictive value of pre-clinical efficacy models, limited understanding of relevant mechanism of action, inability of large molecules to cross the BBB and undermining the heterogeneity of neurobiological phenotypes pose as key obstacles.